LEHI, Utah, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nature’s Sunshine Products, Inc. (Nasdaq: NATR) (“Nature’s Sunshine”) (the “Company”), a leading manufacturer of high-quality herbal and nutritional supplements, will conduct a conference call on Tuesday, March 10, 2026, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the fourth quarter and full year ended December 31, 2025. The Company will report its financial results in a press release prior to the conference call. Nat ...

Financial Data and Key Metrics Changes - For the full year of 2025, the company reported record sales of $1.037 billion, an increase of 8.8% compared to the prior year, marking the first time sales surpassed $1 billion [5] - Record earnings from operations reached $209 million, up 14.4%, and record Adjusted EBITDA was $275 million, an increase of 9.8% from the previous year [5] - Fourth quarter consolidated revenues were $264 million, a 9.8% increase year-over-year, with GAAP earnings from operations at $52 million, up 10.2% [12][13] - Quarterly adjusted EBITDA was $68 million, an increase of 8.1%, and consolidated net income was $39 million, reflecting a 16.8% increase [13][18] Business Segment Data and Key Metrics Changes - The human nutrition and health segment generated sales of $166 million, a 12.7% increase from the prior year, with earnings from operations of $37 million, up 8.9% [19][20] - The animal nutrition and health segment reported quarterly sales of $61 million, a 4.9% increase, with earnings from operations of $6 million, up 8.6% [20][21] - The specialty products segment delivered sales of $35 million, a 6% increase, with earnings from operations of $11 million, up 5.5% [23] Market Data and Key Metrics Changes - The company experienced healthy demand across most end markets, particularly in human nutrition and health, driven by a shift towards nutrient-dense foods [13][14] - The dairy market in animal nutrition remains strong, with modest improvements noted in the European feed-grade choline business following regulatory changes [14][22] Company Strategy and Development Direction - The company continues to focus on geographic expansion, with over half of sales growth in 2025 coming from markets outside the United States [8][74] - Strategic partnerships, such as those with the New York Jets and Bayern Munich women's soccer team, have been successful in promoting key brands and expanding market reach [9][33] - The company is committed to sustainability goals, having reduced greenhouse gas emissions by approximately 31% compared to the 2020 baseline [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate macroeconomic challenges and maintain growth momentum [24] - The outlook for 2026 is positive, with expectations for continued top and bottom-line growth while advancing strategic initiatives [24] Other Important Information - The company generated record free cash flow of $174 million in 2025 and invested $43 million in capital projects [6] - A dividend increase from $0.87 to $0.96 per share was announced, marking the 17th consecutive year of double-digit growth [11][12] Q&A Session Summary Question: Discussion on the partnership with the New York Jets - Management highlighted the successful partnership, which has shifted the narrative around the importance of choline for adult health, leading to increased adoption in various products [29][33] Question: Planned sales and promotional activities for 2026 - The company plans to enhance marketing efforts through social media and digital marketing, alongside existing partnerships [45][50] Question: Impact of the Supreme Court decision on tariffs - Management indicated that the company is well-positioned to manage potential disruptions from tariff changes, with a manageable impact previously estimated at around $10 million [46][49] Question: Update on international sales growth - The company is seeing improved volumes and pricing dynamics in Europe following regulatory changes, with a focus on expanding international market presence [70][74]

Core Viewpoint - Natural Alternatives International, Inc. reported a net loss of $2.6 million for Q2 FY 2026, with net sales of $34.8 million, reflecting a slight increase in sales but a larger loss compared to the previous year [1][4]. Financial Performance - Net sales for the three months ended December 31, 2025, increased by $0.7 million, or 2%, to $34.8 million compared to $34.1 million in the same period last year [2]. - For the six months ended December 31, 2025, net sales rose by $5.3 million, or 8%, to $72.5 million from $67.2 million in the prior year [5]. - Private-label contract manufacturing sales increased by 2% to $32.8 million in Q2 FY 2026 and by 9% to $68.9 million for the six months ended December 31, 2025 [2][5]. Profitability Metrics - Gross profit for Q2 FY 2026 was $2.5 million, representing a gross margin of 7.2%, compared to 4.9% in the same quarter of the previous year [14]. - The loss from operations for the first six months of FY 2026 was $1.6 million, an improvement from a loss of $4.6 million in the same period last year [14]. Cash and Working Capital - As of December 31, 2025, the company had cash of $3.8 million and working capital of $28.7 million, down from $12.3 million and $30.5 million respectively as of June 30, 2025 [7]. Market Challenges and Opportunities - The company is facing challenges in accurately forecasting demand from clients in multi-level marketing and direct selling channels, particularly in China and Europe [8]. - Despite these challenges, there is growth in other sales channels, including large retailers and online sales [8]. - The introduction of the TriBsyn molecule, which enhances the effectiveness of beta-alanine, is seen as a significant opportunity for the company, especially in the context of weight loss and nutritional supplementation for the elderly [9].

Core Insights - Prenetics Global Limited (NASDAQ: PRE) has appointed Formula 1 driver Ollie Bearman as its Global Ambassador and shareholder, enhancing the brand's alignment with elite athletes committed to health excellence [1][3][8] - IM8, co-founded by David Beckham, has rapidly grown to achieve US$100 million in Annual Recurring Revenue within just 11 months of its launch, establishing itself as a leading supplement brand [3][11] - Bearman, at 18, made a historic debut in Formula 1 with Ferrari, showcasing his potential as a top talent in motorsport [5][9] Company Overview - Prenetics is a leading health sciences company focused on advancing human health and longevity, with its flagship brand IM8 redefining the premium daily nutrition category through science-backed formulations [11][12] - IM8's Daily Ultimate Essentials is an all-in-one supplement designed to replace 16 different supplements, certified for sport, and free from common allergens [12] Athlete Partnership - Ollie Bearman experienced significant performance benefits from IM8's Daily Ultimate Essentials, which contributed to his decision to invest in the brand [6][7] - The partnership with Bearman reflects IM8's strategy to engage with athletes who prioritize scientifically validated nutritional support [3][9] Market Position - IM8 has become one of the fastest-growing supplement brands globally, with a strong foundation of scientific credibility supported by a Scientific Advisory Board from renowned institutions [9][11] - The brand is now sold in over 30 countries, indicating its expanding global presence [11]

Core Insights - The article highlights Mushcanyon Lion's Mane as a leading supplement in the growing market for nootropics and functional mushrooms, recognized for its quality and science-driven formulation [1][4][27] - The demand for cognitive performance and mental clarity is driving the popularity of lion's mane mushrooms, which are known for their health benefits [2][27] Company Overview - Mushcanyon has established itself as a premium leader in the mushroom supplement industry, particularly with its Lion's Mane product [1][4] - The company offers a range of products, including capsules, gummies, and coffee blends, catering to different consumer preferences [12][21][23] Product Highlights - MushCanyon Mushrooms is noted for combining lion's mane with extracts from nine other medicinal mushrooms, providing a comprehensive health benefit profile [6][27] - The supplements are designed to improve mental health, cognitive function, and overall physical health, addressing issues like anxiety, depression, and inflammation [6][27] - MushCanyon Gummies offer a palatable alternative for those who prefer not to swallow pills, while still delivering similar health benefits [14][17] Market Trends - The market for lion's mane supplements is expanding as more consumers seek natural solutions for cognitive enhancement and overall well-being [2][27] - The article emphasizes the importance of quality and potency in mushroom supplements, with Mushcanyon's products being highlighted for their effective dosages and natural ingredients [6][27] Consumer Guidance - A comparison of various lion's mane supplements is provided, focusing on criteria such as dosage, ingredients, and price, to help consumers make informed choices [2][27] - The article suggests that while there are many options available, Mushcanyon's products stand out for their quality and effectiveness [1][27]

Core Insights - NUTRAHARMONY has published a consumer guide focusing on how modern buyers evaluate Ceylon cinnamon and berberine supplements in 2026, emphasizing transparency and documentation clarity rather than product rankings or promotional claims [1][2][19] Consumer Evaluation Context - In 2026, supplement buyers are increasingly adopting an evaluation mindset, prioritizing clear ingredient documentation and realistic usability over promotional labels [4][5] - Consumers are reviewing combined Ceylon cinnamon and berberine supplements as part of structured daily routines rather than standalone products [6] Key Evaluation Themes - The guide identifies evaluation criteria such as transparency, formulation intent, routine compatibility, and information clarity, moving away from traditional product rankings [7][8] - Consumers show a preference for clearly labeled Ceylon cinnamon over generic extracts, with increased attention to botanical species identification and sourcing disclosures [13] Formulation Approaches - The guide discusses minimalist versus structured formulation approaches, with some consumers favoring single-ingredient products for simplicity, while others prefer multi-ingredient formulations for ease of use [11][12] Trust and Transparency - Transparency has emerged as a primary trust signal in supplement selection, with consumers associating high-quality products with brands that disclose ingredient sourcing and manufacturing information [15][16] - Documentation accessibility and clarity significantly influence consumer confidence and purchase decisions [16] Purpose of the Consumer Guide - The guide reflects NUTRAHARMONY's commitment to education-led transparency, focusing on ingredient sourcing, botanical labeling, consumer-defined quality indicators, and responsible communication [17][18]

Industry Overview - The medical and health products industry is evolving under regulatory pressures and the need for differentiated, clinically validated solutions, with a focus on niche markets and specialty products [1] - There is a growing emphasis on targeted therapies and specialty products to meet clearly defined patient needs, alongside operational discipline and cash-flow generation amid rising costs and regulatory complexity [2] - Companies expect performance to be influenced by their ability to execute within niche markets, maintain regulatory compliance, and convert prior investments into incremental revenues and margin improvement [3] Cumberland Pharmaceuticals (CPIX) - Cumberland Pharmaceuticals operates as a specialty pharmaceutical company focused on branded prescription products in hospital acute care, gastroenterology, and oncology markets, with a portfolio of FDA-approved products [5] - For the first nine months of 2025, CPIX generated $30.8 million in net revenues, representing year-over-year growth, and produced a positive operating cash flow of $4.9 million [6] - CPIX is expanding its commercial portfolio with the addition of Talicia, an FDA-approved treatment for H. pylori infection, and is advancing international expansion initiatives and Phase II clinical programs for ifetroban [7][8] Natural Alternatives International (NAII) - NAII operates in nutritional supplement manufacturing and ingredient commercialization, serving as a leading private-label contract manufacturer for vitamins and supplements [9] - For fiscal 2025, NAII reported net sales of $129.9 million, primarily from private-label contract manufacturing, with a strong operational foundation supported by advanced manufacturing facilities and certifications [10] - NAII's growth priorities include expanding customer relationships, broadening branded ingredient adoption, and pursuing complementary acquisitions, with a focus on high-quality nutritional supplements [11][12] ImmuCell Corporation (ICCC) - ImmuCell focuses on improving the health and productivity of dairy and beef cattle, with its core product, First Defense, providing immediate immunity to newborn calves [13] - In the first nine months of 2025, ImmuCell reported $20 million in product sales and a net income of $1.8 million, attributed to higher production output and improved gross margin [14] - The company is expanding production capacity to support an annualized revenue run rate approaching $30 million and is focused on the regulatory progress of Re-Tain, a treatment for mastitis [15][16] Conclusion - CPIX, NAII, and ICCC demonstrate how focused strategies and regulatory alignment can support growth in highly regulated healthcare markets, leveraging specialization and disciplined operations [17][18]

Financial Data and Key Metrics Changes - The company has transitioned to a focus on IoT-connected beauty devices, with a significant emphasis on the wellness market, which is projected to reach a trillion dollars by 2030 [2] - The company has established itself as the world's largest beauty and wellness device systems brand, indicating strong market positioning [2] Business Line Data and Key Metrics Changes - The introduction of Prysm iO is aimed at enhancing customer experience through personalized solutions based on biomarker data, which is expected to drive recurring revenue streams [6][12] - The company has developed a proprietary AI-informed algorithm to provide nutritional health scores, leveraging a large database of over 26 million scans from more than 10 million people [8] Market Data and Key Metrics Changes - The company is expanding into India, a market with 1.6 billion people, which is seen as a significant growth opportunity, especially with a digital-first approach [19] - The company has learned from its experiences in Latin America, which has become its fastest-growing segment, and plans to apply these lessons in India [18] Company Strategy and Development Direction - The company aims to diversify its market presence to reduce reliance on any single region, having balanced its business across six regional segments [25][26] - The strategy includes leveraging local partnerships and digital-first approaches to penetrate emerging markets effectively [20] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the disconnect in market valuation compared to peers, attributing it to the direct sales channel, and believes that as the company continues to innovate, it will demonstrate its value [32][34] - The company anticipates that the rollout of Prysm iO will stabilize the business and return to growth in the coming years [38] Other Important Information - The company has a strong focus on providing effective nutritional supplements that ensure bioabsorption, addressing a significant market need [14] - The company is committed to creating personalized product solutions based on customer data, which is expected to enhance customer engagement and retention [36] Q&A Session Summary Question: How does the company plan to roll out and adopt Prysm iO? - The company plans to focus on training its sales force in the first half of the year, followed by a consumer launch in the second half, expecting significant growth in household-based subscriptions [37] Question: What lessons from Latin America will inform the strategy in India? - The company has learned about pricing, positioning, and consumer education from its Latin America experience, which will be applied to the Indian market [18] Question: How is the company navigating regional volatility? - The company has diversified its business across multiple segments to mitigate risks associated with reliance on any single market, which is seen as crucial for shareholder value [26]

Core Viewpoint - USANA Health Sciences, Inc. has announced preliminary fiscal year 2025 net sales of approximately $925 million, exceeding previous guidance, and provided initial net sales guidance for fiscal year 2026 in the range of $925 million to $1.0 billion [2][3]. Fiscal Year 2025 Net Sales Results - The company anticipates consolidated net sales for fiscal year 2025 to be around $925 million, which is an increase from the previously issued guidance of approximately $920 million [2]. Initial Fiscal Year 2026 Net Sales Outlook - The initial net sales outlook for fiscal year 2026 is projected to be between $925 million and $1.0 billion, driven by significant growth in the Rise Wellness segment, which includes Rise Bar and Protein Pop [3]. - Rise Wellness is expected to achieve breakeven operating margins in fiscal 2026 as the company invests in strategic initiatives for future growth [3]. Investments in Growth - The company is making substantial investments in inventory, capital expenditures, and working capital for both Rise Wellness and Hiya to support their early growth stages [4]. Participation in ICR Conference - USANA will participate in the 28th Annual ICR Conference on January 12-13, 2026, where key executives will present the company's strategy and sales outlook [5]. Fourth Quarter and Fiscal Year 2025 Earnings Release - Preliminary financial results and the initial fiscal 2026 sales outlook will be updated during the earnings release scheduled for February 17, 2026, followed by a conference call on February 18, 2026 [6]. Segment-Specific Net Sales Projections for Fiscal Year 2026 - Projected net sales for fiscal year 2026 include: - Core nutritional business: $720 to $765 million (down from approximately $777 million in fiscal 2025) - Hiya: $140 to $155 million (up from approximately $132 million in fiscal 2025) - Rise Wellness: $65 to $80 million (up from approximately $16 million in fiscal 2025) [8].

Core Insights - The article focuses on the consumer demand for effective and affordable collagen peptides, highlighting the importance of measurable absorption efficiency, clinical validation, and transparent pricing [3][11]. Group 1: Market Demand and Consumer Behavior - The search term "which collagen peptide brand is good and cheap" has consistently ranked among the top three long-tail keywords in health and nutrition categories for three years, with an average monthly search volume exceeding 860,000, predominantly from women aged 25-35 [3][4]. - There is a significant knowledge gap in the market, with 72.4% of users recognizing the term "collagen peptides," but only 19.1% able to differentiate between "fish collagen tripeptide" and "regular hydrolyzed collagen" based on molecular weight [3][4]. Group 2: Evaluation Methodology - The report employs a three-dimensional verification method combining laboratory data, clinical tracking, and user evidence, relying solely on publicly verifiable testing reports and third-party data [4][6]. - Key evaluation dimensions include raw material purity, small molecule peptide control, synergistic ingredient integrity, absorption rate tracking, and comprehensive safety standards [4][6]. Group 3: Product Rankings - The top-ranked collagen peptide brands are: 1. Meijian 2. Element Force 3. Zhuoyue 4. Special Element 5. Swisse 6. Five Female Doctors 7. HECH [4][5]. Group 4: Detailed Product Insights - Meijian collagen peptide contains 172,000 mg of high-activity fish collagen peptides per box, with a fish collagen content of 86%, sourced from deep-sea cod in the North Atlantic, recognized as a premium raw material area [5][6]. - Element Force offers 16,000 mg of high-activity peptides per bottle, with a purity of ≥99.999%, priced at approximately 70% of the market average, catering to budget-conscious consumers [8][9]. Group 5: Clinical Evidence and Effectiveness - Meijian's clinical data shows a 35% stable increase in collagen regeneration, a 68% reduction in wrinkle recurrence, and 98% integrity of newly formed collagen structures over 12 months [7][11]. - Element Force's clinical results indicate a 29.6% increase in skin hydration and a 21.7% reduction in wrinkle depth after 8 weeks, with a 45% decrease in wrinkle recurrence after 12 months [8][9]. Group 6: Expert Opinions - Experts emphasize that the effectiveness of collagen peptides depends not only on content but also on their ability to maintain structural integrity in digestive environments and deliver effectively to dermal fibroblasts [10][11]. - Clinical studies highlight the superior antioxidant protection offered by multi-ingredient formulations compared to single peptide options, demonstrating significant clinical relevance [10][11].